Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
Cure8 research brief
Why This Matters
Muscle loss (myopenia) can persist in Crohn's disease even after weight recovery and clinical remission, which may affect long-term outcomes. Identifying persistent muscle depletion with body composition measures could prompt earlier nutritional and rehabilitative interventions.
Who Should Pay Attention
Patients with Crohn's disease (newly diagnosed or with significant weight loss), gastroenterologists, dietitians, and IBD care teams
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The report highlights that body weight and clinical remission may not reflect recovery of skeletal muscle. Computed tomography–based body composition analysis and bioelectrical measures identified ongoing myopenia despite ~25% weight regain, increased adipose tissue, and improved dietary intake.
The authors suggest early nutritional assessment and longitudinal body composition monitoring to detect and address persistent muscle depletion.
Keep In Mind
This classification and note are based on the article abstract (case report) from Nutrition in Clinical Practice. As a single-patient report, it illustrates an issue but cannot determine how common this is or the best corrective strategies.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationNutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
AuthorsBeatriz Gabriela da Costa, Jeniffer Naomy Nobre, Ryan Nunes Yoshio Yoshihara +8 more
InstitutionDepartment of Internal Medicine, Medical School, São Paulo State University (Unesp), Botucatu, São Paulo, Brazil.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedOct 14, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Ustekinumab-induced Focal Segmental... : Journal of Nature and Science of Medicine - Ovid
This case suggests ustekinumab — a commonly used biologic for Crohn’s disease — might rarely be associated with kidney injury (FSGS). Patients and clinicians should be aware of new or worsening edema, proteinuria, or...
Do You Need to Treat Asymptomatic Crohn’s Disease?
You can have active intestinal inflammation even without clear symptoms; early monitoring and tailored treatment aim to prevent complications and preserve quality of life.
SURGICAL APPROACH, BIOLOGICAL THERAPIES, AND INFLAMMATORY MECHANISMS ASSOCIATED WITH ULCERATIVE COLITIS AND CROHN'S DISEASE
The review links specific therapies and surgical options to outcomes that matter to people with IBD — mucosal healing, lower hospitalizations, and reduced need for surgery — and highlights that combining medical and...